Efficacy and Safety of Axitinib as First-Line Therapy in Japanese Patients with Metastatic Renal Cell Carcinoma

摘要: Previous study reported that patients treated with axitinib as second-line therapy had longer median progression-free survival than those sorafenib for metastatic renal cell carcinoma (mRCC). In this study, we reviewed our experience of a first-line mRCC in Japanese patients, focusing on its efficacy and safety. We retrospectively assessed 26 from July 2010 to 2014 at Chiba Cancer Center Kinki University Hospital. Observation period was 24.6 ± 18.3 months. The objective response rate 50.0%, the 27.5 Overall not estimable. Common grade 3 adverse events were hypertension 19 proteinuria 5 patients. Axitinib demonstrated significant mRCC. Careful monitoring management effects may help control toxicities.